title: The malaria vaccine development program in Papua New Guinea.
abstract: Through a collaborative project led by the Papua New Guinea Institute of Medical Research (PNGIMR), Papua New Guinea has a significant role in the global effort to develop a malaria vaccine, ensuring that the malaria patterns in Asia and the Pacific region are considered in vaccine development strategies. Some of the major perspectives and achievements of the program are discussed here, one of the most successful being the trial of Combination B, a vaccine comprising three asexual blood-stage proteins [merozoite surface protein (MSP)1, MSP2 and ring-infected erythrocyte surface antigen (RESA)], which led to a considerable reduction of parasite density in the immunized children.
authors.affiliation: Swiss Tropical Institute, Socinstrasse 57, 4002 Basel, Switzerland. blaise.genton@hospvd.ch
authors.forename: Blaise
authors.initials: B
authors.lastname: Genton
authors.forename: Robin F
authors.initials: RF
authors.lastname: Anders
authors.forename: Michael P
authors.initials: MP
authors.lastname: Alpers
authors.forename: John C
authors.initials: JC
authors.lastname: Reeder
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000592:standards; D006801:Humans; D008288:Malaria / Q000453:epidemiology / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000145:classification; D010219:Papua New Guinea / Q000453:epidemiology; D012106:Research / Q000458:organization & administration* / Q000592:standards / Q000639:trends
chemical_list: D017780:Malaria Vaccines